North America NGS-based RNA-sequencing Market, 2025-2035
The North America NGS-based RNA-sequencing market continues to evolve rapidly, driven by technological advances, expanding clinical and research applications, and growing investments in precision medicine. Increasing demand for high-throughput sequencing for genomic and transcriptomic analyses is propelling market growth across both the United States and Canada. The adoption of robust RNA-seq workflows by research institutions, clinical diagnostic labs, and biopharmaceutical companies is strengthening market share among leading players. Heightened government and private funding, alongside the introduction of next-generation platforms and automation, is expected to push overall revenue to new highs by 2035, with increasing application in drug discovery, biomarker development, and personalized medicine.
Latest Market Dynamics
Key Drivers
- Rising demand for precision and personalized medicine is accelerating the adoption of NGS-based RNA-sequencing, with major companies like Illumina Inc. launching advanced sequencing solutions tailored for clinical testing and research use.
- Significant reduction in sequencing costs and increased throughput, as seen with technological progress from companies such as Thermo Fisher Scientific, are boosting accessibility and driving broader market uptake in North America.
Key Trends
- Integration of artificial intelligence and machine learning into RNA-seq workflows to enable faster bioinformatic analyses and interpretation of complex multi-omics datasets, with companies like QIAGEN leading efforts in deploying AI-driven platforms.
- A shift towards single-cell RNA sequencing and spatial transcriptomics, as demonstrated through recent product launches by 10x Genomics and Pacific Biosciences, supporting higher-value applications in oncology and neurobiology.
Key Opportunities
- Expansion of NGS-based RNA-sequencing applications in companion diagnostics and clinical trials represents a major opportunity, supported by partnerships between biopharma firms and sequencing providers such as Roche and Agilent Technologies.
- Accelerating government and institutional investment in genomics infrastructure across the US and Canada is fostering R&D and expanding commercialization prospects for vendors like Illumina and Oxford Nanopore Technologies.
Key Challenges
- Data management and storage complexities due to the massive volume of datasets generated by next-generation RNA-sequencing remain a significant challenge, with firms like Amazon Web Services providing genomic cloud solutions but barriers to widespread adoption still exist.
- Standardization of protocols and bioinformatic pipelines remains inconsistent across research and clinical labs, causing data reproducibility issues despite efforts by organizations such as the Global Alliance for Genomics & Health (GA4GH).
Key Restraints
- High initial capital investment for sequencing platforms and reagents continues to restrain adoption, with mid- and small-scale labs facing budget constraints despite pricing improvements by manufacturers.
- Concerns over regulatory compliance and data privacy, especially when handling patient-derived transcriptomic information, are prompting more cautious adoption by healthcare institutions and life science firms.
Market Share (%) by Type, 2025
Among various NGS-based RNA-sequencing types, mRNA sequencing is anticipated to dominate the North America market in 2025, driven by its widespread use in gene expression profiling and disease research. This segment is closely followed by small RNA sequencing, widely adopted for miRNA and other non-coding RNA studies in functional genomics, and targeted RNA sequencing, which is gaining traction for its cost-effective approach to analyzing gene panels. The clear dominance of mRNA sequencing is a reflection of ongoing demand in both academic and clinical settings, propelling companies to launch more sensitive and scalable solutions.
Market Share (%) by Application, 2025
Diagnostics is poised to be the leading application for NGS-based RNA-sequencing in North America by 2025, as hospitals and clinical labs increasingly incorporate transcriptomic data into oncology and rare disease diagnosis. Closely behind, drug discovery is leveraging RNA-seq for target identification and safety assessments, while biomarker discovery continues to gain momentum with a surge in translational research programs. This broadening adoption across healthcare and pharmaceutical research is expected to drive continued growth and innovation throughout the forecast period.
Market Revenue (USD Million), 2020–2035
The North America NGS-based RNA-sequencing market is expected to exhibit steady revenue growth from 2020 through 2035, underpinned by rapid technology adoption, expanding clinical applications, and increasing R&D spending. In 2025, total market revenue is projected to reach approximately 1,350 Million USD, with a sustained annual growth rate driven by advancements in sequencing technologies, integration of automation, and higher throughput capabilities. The market is forecast to surpass 3,540 Million USD by 2035 as genetic and transcriptomic profiling become routine in both academic and clinical environments.
YOY Growth Rate (%), 2020–2035
Year-over-year (YOY) growth in the North America NGS-based RNA-sequencing market is predicted to remain strong throughout the forecast window, peaking as new sequencers, cloud-based analysis tools, and AI-driven workflows are broadly adopted. YOY growth is expected to average around 8.3% from 2025 to 2030, gradually moderating to 5.7% by 2035 as the market matures and high-volume clinical use stabilizes in North America.
Market Share (%) by Region, 2025
In 2025, the United States is forecast to command by far the highest regional market share for NGS-based RNA-sequencing in North America, attributed to strong research funding, advanced infrastructure, and rapid clinical adoption. Canada and Mexico are slated for steady growth, each benefiting from increased investments in genomics but at a lower volume compared to the US. The market hierarchy reflects ongoing trends in biotech innovation, healthcare implementation, and government-driven genomic research initiatives.
Market Share (%) by Leading Players, 2025
Illumina Inc. retains its leadership position in the North America NGS-based RNA-sequencing market for 2025, due to its commanding share of installed sequencer base and widespread adoption of its library preparation kits. Thermo Fisher Scientific and QIAGEN continue to strengthen their presence through robust consumable portfolios and data analysis solutions. This competitive landscape is marked by ongoing product innovation, strategic partnerships, and aggressive expansion tactics among major industry participants.
Market Share (%) by Major Buyer Groups, 2025
In North America, academic and research institutions represent the largest buyer group for NGS-based RNA-sequencing platforms and services, accounting for a substantial portion of overall demand. Clinical laboratories, driven by adoption in diagnostics and personalized medicine, form the next major segment, while pharmaceutical and biotechnology firms follow closely as they increasingly invest in RNA-seq for drug and biomarker discovery applications.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1350 |
| Regions | US, Canada, Mexico |
| Segments | By Type: mRNA Sequencing, miRNA Sequencing, De novo Transcriptome Assembly, Small RNA Sequencing, Whole Transcriptome Sequencing, Targeted RNA Sequencing; By Application: Diagnostics, Drug Discovery, Biomarker Discovery, Toxicogenomics, Personalized Medicine, Others |
| Players | Illumina Inc., Thermo Fisher Scientific, Agilent Technologies, QIAGEN, BGI, PerkinElmer Inc., Pacific Biosciences, F. Hoffmann-La Roche AG, Lexogen GmbH, Takara Bio Inc., Oxford Nanopore Technologies, Arraystar Inc., NuGEN Technologies (TECAN Group), Eurofins Scientific, Macrogen Inc. |
Key Recent Developments
- June 2024: Illumina launched its new NovaSeq X Plus platform aimed at making high-throughput RNA-seq more accessible for clinical labs and genomic research entities across North America.
- July 2024: Thermo Fisher Scientific announced an expansion of its Ion Torrent Genexus System with advanced RNA panel capabilities, supporting streamlined translational medicine workflows.
- August 2024: QIAGEN introduced QIAseq Single Cell RNA-seq Kits, optimized for multi-omics integration and high-resolution transcriptomic profiling in single-cell applications.
- September 2024: Pacific Biosciences partnered with leading cancer centers in the US to pilot HiFi long-read RNA sequencing in oncology diagnostics and biomarker development.
- October 2024: Oxford Nanopore Technologies unveiled updated flow cells, reducing sequencing costs and turnaround times for targeted and full-length RNA profiling in North American labs.
